Lexicon Pharmaceuticals (LXRX) vs Pharming Group N.V. (PHAR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Lexicon Pharmaceuticals (LXRX) has outperformed Pharming Group N.V. (PHAR) over the past year, gaining 7.0% versus a loss of 33.1%. Over five years, PHAR leads with a -0.6% price change compared with -70.2% for LXRX. Lexicon Pharmaceuticals is the larger company by market cap ($676.3 million vs $662.5 million), about 1.0 times the size.
Pharming Group N.V. converts more of its revenue into profit, with a net margin of 0.8% versus -101.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LXRX | PHAR |
|---|---|---|
| Share price | $1.52 | $9.36 |
| Market cap | $676.33M | $662.48M |
| 1-day change | -7.88% | -2.40% |
| YTD return | +32.17% | -47.03% |
| 1-year return | +7.04% | -33.14% |
| 5-year return | -70.20% | -0.64% |
| P/E ratio (TTM) | — | 72.00 |
| Forward P/E | — | 142.90 |
| EPS (TTM) | $-0.16 | $0.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $49.80M | $376.13M |
| Revenue growth (YoY) | +60.24% | +26.56% |
| Net income (latest FY) | $-50.34M | $2.85M |
| Gross margin | 99.45% | 87.90% |
| Operating margin | -98.21% | 6.87% |
| Net margin | -101.08% | 0.76% |
| 52-week high | $2.68 | $21.34 |
| 52-week low | $1.10 | $9.31 |
| Distance from 52-week high | -43.28% | -56.14% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +199.34% | +266.99% |
| Average volume | 2.84M | 23.08K |
| Shares outstanding | 444.96M | 70.78M |
| Employees | 81 | 407 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LXRX has outperformed PHAR by 40.2 percentage points over the past year.
- Pharming Group N.V. is more profitable, keeping 0.8 cents of every revenue dollar as net income versus -101.1 cents for Lexicon Pharmaceuticals.
- Lexicon Pharmaceuticals grew revenue faster in its latest fiscal year (+60.24% vs +26.56%).
About Lexicon Pharmaceuticals
LXRX stock →Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees
About Pharming Group N.V.
PHAR stock →Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 407 employees
LXRX vs PHAR FAQ
Which is bigger, Lexicon Pharmaceuticals or Pharming Group N.V.?
Lexicon Pharmaceuticals (LXRX) is larger, with a market capitalization of $676.33M compared with $662.48M for Pharming Group N.V. (PHAR).
Which stock has performed better over the past year, LXRX or PHAR?
LXRX returned +7.04% over the past 12 months, compared with -33.14% for PHAR (price return, excluding dividends). Past performance does not predict future results.
Are Lexicon Pharmaceuticals and Pharming Group N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.